Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability

Eileen L. Yoon, Jong Eun Yeon, Hyun Jung Lee, Sang Jun Suh, Sun Jae Lee, Seong Hee Kang, Keunhee Kang, Yang Jae Yoo, Ji Hoon Kim, Hyung Joon Yim, Kwan Soo Byun

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

GOALS:: The goal of the study was to compare the efficacy and safety of sorafenib with those of systemic cytotoxic chemotherapy. BACKGROUND:: Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo. However, whether sorafenib controls advanced-stage HCC better than systemic cytotoxic chemotherapy has not been elucidated. STUDY:: We retrospectively reviewed the medical records of 220 patients with measurable advanced HCC who had not received systemic treatment previously between January 2007 and April 2012. Among these patients, 78 had been treated with sorafenib. Another 14 patients who were treated with a 4-weekly regimen of adriamycin, cisplatin, and capecitabine were included as the historical control group for comparison. The median overall survival, the progression-free survival, response rates, and safety profiles were evaluated. RESULTS:: Baseline characteristics were similar between the treatment groups. The median overall survival was 7.2 months [95% confidence interval (CI), 5.6-8.8] in the sorafenib group and 11.2 months (95% CI, 8.1-14.2) in the cytotoxic chemotherapy group (P=0.10). The median progression-free survival was 3.2 months (95% CI, 2.2-4.3) in the sorafenib group and 5.9 months (95% CI, 3.6-8.2) in the cytotoxic chemotherapy group (P=0.07). The deterioration of liver function and neutropenia were the most frequent serious adverse events in the sorafenib and the systemic chemotherapy group. CONCLUSIONS:: Although a direct head-to-head comparison could not be done, there were some patients who showed a good response to systemic cytotoxic chemotherapy. Further assessment is necessary to study the role of chemotherapy in patients who are intolerant or intractable to sorafenib.

Original languageEnglish
JournalJournal of Clinical Gastroenterology
Volume48
Issue number3
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Hepatocellular Carcinoma
Drug Therapy
Confidence Intervals
Disease-Free Survival
Survival
Safety
sorafenib
Neutropenia
Doxorubicin
Cisplatin
Medical Records
Therapeutics
Survival Rate
Placebos
Control Groups
Liver

Keywords

  • Cytotoxic chemotherapy
  • Hepatocellular carcinoma
  • Sorafenib
  • Survival rate

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. / Yoon, Eileen L.; Yeon, Jong Eun; Lee, Hyun Jung; Suh, Sang Jun; Lee, Sun Jae; Kang, Seong Hee; Kang, Keunhee; Yoo, Yang Jae; Kim, Ji Hoon; Yim, Hyung Joon; Byun, Kwan Soo.

In: Journal of Clinical Gastroenterology, Vol. 48, No. 3, 01.03.2014.

Research output: Contribution to journalArticle

@article{a0e75bd58f25449d82a0e961a5427985,
title = "Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability",
abstract = "GOALS:: The goal of the study was to compare the efficacy and safety of sorafenib with those of systemic cytotoxic chemotherapy. BACKGROUND:: Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo. However, whether sorafenib controls advanced-stage HCC better than systemic cytotoxic chemotherapy has not been elucidated. STUDY:: We retrospectively reviewed the medical records of 220 patients with measurable advanced HCC who had not received systemic treatment previously between January 2007 and April 2012. Among these patients, 78 had been treated with sorafenib. Another 14 patients who were treated with a 4-weekly regimen of adriamycin, cisplatin, and capecitabine were included as the historical control group for comparison. The median overall survival, the progression-free survival, response rates, and safety profiles were evaluated. RESULTS:: Baseline characteristics were similar between the treatment groups. The median overall survival was 7.2 months [95{\%} confidence interval (CI), 5.6-8.8] in the sorafenib group and 11.2 months (95{\%} CI, 8.1-14.2) in the cytotoxic chemotherapy group (P=0.10). The median progression-free survival was 3.2 months (95{\%} CI, 2.2-4.3) in the sorafenib group and 5.9 months (95{\%} CI, 3.6-8.2) in the cytotoxic chemotherapy group (P=0.07). The deterioration of liver function and neutropenia were the most frequent serious adverse events in the sorafenib and the systemic chemotherapy group. CONCLUSIONS:: Although a direct head-to-head comparison could not be done, there were some patients who showed a good response to systemic cytotoxic chemotherapy. Further assessment is necessary to study the role of chemotherapy in patients who are intolerant or intractable to sorafenib.",
keywords = "Cytotoxic chemotherapy, Hepatocellular carcinoma, Sorafenib, Survival rate",
author = "Yoon, {Eileen L.} and Yeon, {Jong Eun} and Lee, {Hyun Jung} and Suh, {Sang Jun} and Lee, {Sun Jae} and Kang, {Seong Hee} and Keunhee Kang and Yoo, {Yang Jae} and Kim, {Ji Hoon} and Yim, {Hyung Joon} and Byun, {Kwan Soo}",
year = "2014",
month = "3",
day = "1",
doi = "10.1097/MCG.0b013e3182a54ec8",
language = "English",
volume = "48",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability

AU - Yoon, Eileen L.

AU - Yeon, Jong Eun

AU - Lee, Hyun Jung

AU - Suh, Sang Jun

AU - Lee, Sun Jae

AU - Kang, Seong Hee

AU - Kang, Keunhee

AU - Yoo, Yang Jae

AU - Kim, Ji Hoon

AU - Yim, Hyung Joon

AU - Byun, Kwan Soo

PY - 2014/3/1

Y1 - 2014/3/1

N2 - GOALS:: The goal of the study was to compare the efficacy and safety of sorafenib with those of systemic cytotoxic chemotherapy. BACKGROUND:: Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo. However, whether sorafenib controls advanced-stage HCC better than systemic cytotoxic chemotherapy has not been elucidated. STUDY:: We retrospectively reviewed the medical records of 220 patients with measurable advanced HCC who had not received systemic treatment previously between January 2007 and April 2012. Among these patients, 78 had been treated with sorafenib. Another 14 patients who were treated with a 4-weekly regimen of adriamycin, cisplatin, and capecitabine were included as the historical control group for comparison. The median overall survival, the progression-free survival, response rates, and safety profiles were evaluated. RESULTS:: Baseline characteristics were similar between the treatment groups. The median overall survival was 7.2 months [95% confidence interval (CI), 5.6-8.8] in the sorafenib group and 11.2 months (95% CI, 8.1-14.2) in the cytotoxic chemotherapy group (P=0.10). The median progression-free survival was 3.2 months (95% CI, 2.2-4.3) in the sorafenib group and 5.9 months (95% CI, 3.6-8.2) in the cytotoxic chemotherapy group (P=0.07). The deterioration of liver function and neutropenia were the most frequent serious adverse events in the sorafenib and the systemic chemotherapy group. CONCLUSIONS:: Although a direct head-to-head comparison could not be done, there were some patients who showed a good response to systemic cytotoxic chemotherapy. Further assessment is necessary to study the role of chemotherapy in patients who are intolerant or intractable to sorafenib.

AB - GOALS:: The goal of the study was to compare the efficacy and safety of sorafenib with those of systemic cytotoxic chemotherapy. BACKGROUND:: Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo. However, whether sorafenib controls advanced-stage HCC better than systemic cytotoxic chemotherapy has not been elucidated. STUDY:: We retrospectively reviewed the medical records of 220 patients with measurable advanced HCC who had not received systemic treatment previously between January 2007 and April 2012. Among these patients, 78 had been treated with sorafenib. Another 14 patients who were treated with a 4-weekly regimen of adriamycin, cisplatin, and capecitabine were included as the historical control group for comparison. The median overall survival, the progression-free survival, response rates, and safety profiles were evaluated. RESULTS:: Baseline characteristics were similar between the treatment groups. The median overall survival was 7.2 months [95% confidence interval (CI), 5.6-8.8] in the sorafenib group and 11.2 months (95% CI, 8.1-14.2) in the cytotoxic chemotherapy group (P=0.10). The median progression-free survival was 3.2 months (95% CI, 2.2-4.3) in the sorafenib group and 5.9 months (95% CI, 3.6-8.2) in the cytotoxic chemotherapy group (P=0.07). The deterioration of liver function and neutropenia were the most frequent serious adverse events in the sorafenib and the systemic chemotherapy group. CONCLUSIONS:: Although a direct head-to-head comparison could not be done, there were some patients who showed a good response to systemic cytotoxic chemotherapy. Further assessment is necessary to study the role of chemotherapy in patients who are intolerant or intractable to sorafenib.

KW - Cytotoxic chemotherapy

KW - Hepatocellular carcinoma

KW - Sorafenib

KW - Survival rate

UR - http://www.scopus.com/inward/record.url?scp=84894044560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894044560&partnerID=8YFLogxK

U2 - 10.1097/MCG.0b013e3182a54ec8

DO - 10.1097/MCG.0b013e3182a54ec8

M3 - Article

C2 - 24045282

AN - SCOPUS:84894044560

VL - 48

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 3

ER -